Kissei Pharmaceutical Co., Ltd. (TYO:4547)

Market Cap	192.75B
Revenue (ttm)	91.70B
Net Income (ttm)	14.50B
Shares Out	41.45M
EPS (ttm)	342.25
PE Ratio	13.59
Forward PE	16.21
Dividend	120.00 (2.56%)
Ex-Dividend Date	Mar 30, 2026

Volume	41,400
Average Volume	51,955
Open	4,665.00
Previous Close	4,690.00
Day's Range	4,635.00 - 4,675.00
52-Week Range	3,480.00 - 4,815.00
Beta	-0.27
RSI	56.57
Earnings Date	Jan 30, 2026

About Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of rena...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 1,778
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4547

Financial Performance

In 2024, Kissei Pharmaceutical's revenue was 88.33 billion, an increase of 16.87% compared to the previous year's 75.58 billion. Earnings were 11.96 billion, an increase of 7.18%.